Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Study Phase : Discovery
Sponsor : Viking Global Investors
Deal Size : $10.0 million
Deal Type : Financing
Details : The funding will be used to continue company's development of proprietary methods in genomic sequencing, artificial intelligence and synthetic biology to discover biomarkers and novel therapeutics to treat immunologic disorders.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 23, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Immunology
Highest Development Status : Discovery
Sponsor : Viking Global Investors
Deal Size : $10.0 million
Deal Type : Financing